Acyclovir: Difference between revisions
No edit summary |
|||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: | *Type: Antiviral: guanosine analog | ||
*Dosage Forms: IV, PO | *Dosage Forms: IV, PO | ||
*Common Trade Names: Zovirax | *Common Trade Names: Zovirax | ||
| Line 8: | Line 8: | ||
**10 mg/kg IV q8h x 10 d | **10 mg/kg IV q8h x 10 d | ||
*Genital/Mucocutaneous HSV | *===[[Herpes Simplex Virus-2|Genital/Mucocutaneous HSV]]=== | ||
**Immunocompetent | **Immunocompetent | ||
***1st episode, Mild-mod: 400 mg PO TID x 7-10 d | ***1st episode, Mild-mod: 400 mg PO TID x 7-10 d | ||
| Line 29: | Line 29: | ||
**Immunocompromised | **Immunocompromised | ||
***10 mg/kg IV q8h x 7 d | ***10 mg/kg IV q8h x 7 d | ||
===[[Herpes Zoster]]=== | |||
*Immunocompetent | |||
**800 mg PO 5x/day x 7 d | |||
*Immunocompromised | |||
**10 mg/kg IV q8h x 7 d | |||
*[[Herpes zoster ophthalmicus]] | *[[Herpes zoster ophthalmicus]] | ||
*800 mg PO 5x/day x 7 d | |||
*HSV prophylaxis in immunocompromised | *HSV prophylaxis in immunocompromised | ||
| Line 40: | Line 46: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*Neonatal HSV | |||
**40-60 mg/kg/day IV divided q12h x 14-21 d | |||
*HSV encephalitis | |||
**3 mo - 11 y/o | |||
***30-45 mg/kg/day IV divided q8h x 14-21 d | |||
**>12 y/o | |||
***30 mg/kg/day IV divided q8h x 14-21 d | |||
*Genital/mucocutaneous HSV | |||
**Immunocompetent | |||
***1st episode, 2-11 y/o | |||
****40-80 mg/kg/day PO divided q6-8 h x 5 d, max 1g/day | |||
***1st episode, >12 y/o | |||
****1g/day PO divided 5x/day x 7-10 d | |||
**Immunocompromised | |||
***PO: >2 y/o: 1g/day PO divided 3-5x/day x 7-14 d | |||
***IV: >1 y/o: 30 mg/kg/day IV divided q8h x 7-14 d | |||
*Varicella | |||
**Immunocompetent | |||
***PO: > 2 y/o: 80 mg/kg/day PO divided q6h x 5 d | |||
***IV: > 1 y/o: 30 mg/kg/day IV divided q8h x 7-10 d | |||
**Immunocompromised | |||
***30 mg/kg/day IV divided q8h x 7-10 d | |||
*Herpes zoster | |||
**Immunocompetent | |||
***PO: > 12 y/o: 4g/day PO divided 5x/day x 5-7 d | |||
***IV: 30 mg/kg/day IV divided q8h x 7-10 d | |||
**Immunocompromised | |||
***30 mg/kg/day IV divided q8h x 7-10 d | |||
==Special Populations== | ==Special Populations== | ||
| Line 65: | Line 100: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Hallucinations / psychosis | |||
*Seizure | |||
*Coma | |||
*Encephalopathy | |||
*Thrombocytopenia | |||
*Leukopenia | |||
*Anaphylaxis | |||
*Angioedema | |||
*Erythema Multiforme | |||
*SJS / TEN / TTP | |||
*Hepatitis | |||
*Renal failure | |||
===Common=== | ===Common=== | ||
*Nausea/vomiting/diarrhea | |||
*Headache | |||
*Dizziness | |||
*Rash | |||
*Arthralgia | |||
*Confusion / lethargy | |||
*Elev. BUN/Cr | |||
*Photosensitivity | |||
==Pharmacology== | ==Pharmacology== | ||
| Line 77: | Line 132: | ||
==Sources== | ==Sources== | ||
*Epocrates 2015 | |||
<references/> | <references/> | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 11:32, 11 March 2015
General
- Type: Antiviral: guanosine analog
- Dosage Forms: IV, PO
- Common Trade Names: Zovirax
Adult Dosing
- HSV Encephalitis
- 10 mg/kg IV q8h x 10 d
- ===Genital/Mucocutaneous HSV===
- Immunocompetent
- 1st episode, Mild-mod: 400 mg PO TID x 7-10 d
- 1st episode, Severe: 5-10 mg/kg IV q8h x 2-7 d
- Recurrence: 400 mg PO TID x 5 d
- Suppression: 400 mg PO BID
- Immunocompromised
- 1st episode: 400 mg PO TID x 5-10 d
- Recurrence: 400 mg PO TID x 5-10 d
- Suppression: 400-800 mg PO BID-TID
- Immunocompetent
- Varicella
- Immunocompetent
- 800 mg PO QID x 5-7 d
- Immunocompromised
- 10 mg/kg IV q8h x 7 d
- Immunocompetent
- Herpes Zoster
- Immunocompetent
- 800 mg PO 5x/day x 7 d
- Immunocompromised
- 10 mg/kg IV q8h x 7 d
- Immunocompetent
Herpes Zoster
- Immunocompetent
- 800 mg PO 5x/day x 7 d
- Immunocompromised
- 10 mg/kg IV q8h x 7 d
- Herpes zoster ophthalmicus
- 800 mg PO 5x/day x 7 d
- HSV prophylaxis in immunocompromised
- 400-800 mg PO BID-TID
- HSV keratitis
- 400 mg PO 5x/day
Pediatric Dosing
- Neonatal HSV
- 40-60 mg/kg/day IV divided q12h x 14-21 d
- HSV encephalitis
- 3 mo - 11 y/o
- 30-45 mg/kg/day IV divided q8h x 14-21 d
- >12 y/o
- 30 mg/kg/day IV divided q8h x 14-21 d
- 3 mo - 11 y/o
- Genital/mucocutaneous HSV
- Immunocompetent
- 1st episode, 2-11 y/o
- 40-80 mg/kg/day PO divided q6-8 h x 5 d, max 1g/day
- 1st episode, >12 y/o
- 1g/day PO divided 5x/day x 7-10 d
- 1st episode, 2-11 y/o
- Immunocompromised
- PO: >2 y/o: 1g/day PO divided 3-5x/day x 7-14 d
- IV: >1 y/o: 30 mg/kg/day IV divided q8h x 7-14 d
- Immunocompetent
- Varicella
- Immunocompetent
- PO: > 2 y/o: 80 mg/kg/day PO divided q6h x 5 d
- IV: > 1 y/o: 30 mg/kg/day IV divided q8h x 7-10 d
- Immunocompromised
- 30 mg/kg/day IV divided q8h x 7-10 d
- Immunocompetent
- Herpes zoster
- Immunocompetent
- PO: > 12 y/o: 4g/day PO divided 5x/day x 5-7 d
- IV: 30 mg/kg/day IV divided q8h x 7-10 d
- Immunocompromised
- 30 mg/kg/day IV divided q8h x 7-10 d
- Immunocompetent
Special Populations
- Pregnancy Rating: B
- Lactation: Safe
- Renal Dosing
- Adult
- IV
- CrCl 25-50 give q12h
- CrCl 10-24 give q24h
- CrCl <10 decr. dose 50%, give q24h
- HD give usual dose as supplement
- PD no supplement
- PO
- CrCl <25: see package insert
- HD: give usual dose as supplement
- PD: no supplement
- IV
- Pediatric
- Adult
- Hepatic Dosing
- Not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Hallucinations / psychosis
- Seizure
- Coma
- Encephalopathy
- Thrombocytopenia
- Leukopenia
- Anaphylaxis
- Angioedema
- Erythema Multiforme
- SJS / TEN / TTP
- Hepatitis
- Renal failure
Common
- Nausea/vomiting/diarrhea
- Headache
- Dizziness
- Rash
- Arthralgia
- Confusion / lethargy
- Elev. BUN/Cr
- Photosensitivity
Pharmacology
- Half-life: 2.5 - 3.3 hrs
- Metabolism: virally infected cells (intracellularly); liver
- Excretion: Urine
- Mechanism of Action: Inhibits DNA polymerase
See Also
Sources
- Epocrates 2015
